InvestorsObserver
×
News Home

Should Drug Manufacturers - General Stock AbbVie Inc (ABBV) Be in Your Portfolio Monday?

Monday, November 29, 2021 03:45 PM | InvestorsObserver Analysts

Mentioned in this article

Should Drug Manufacturers - General Stock AbbVie Inc (ABBV) Be in Your Portfolio Monday?

The 53 rating InvestorsObserver gives to AbbVie Inc (ABBV) stock puts it near the top of the Drug Manufacturers - General industry. In addition to scoring higher than 73 percent of stocks in the Drug Manufacturers - General industry, ABBV’s 53 overall rating means the stock scores better than 53 percent of all stocks.

Overall Score - 53
ABBV has an Overall Score of 53. Find out what this means to you and get the rest of the rankings on ABBV!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With AbbVie Inc Stock Today?

AbbVie Inc (ABBV) stock is trading at $117.06 as of 3:40 PM on Monday, Nov 29, an increase of $0.55, or 0.47% from the previous closing price of $116.51. Volume today is light. So far 2,782,140 shares have traded compared to average volume of 5,612,146 shares. The stock has traded between $116.58 and $117.92 so far today. Click Here to get the full Stock Report for AbbVie Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App